<DOC>
	<DOCNO>NCT01971164</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) sequential ascend dos JTZ-951 administer 15 day anemic subject end-stage renal disease ( ESRD ) receive hemodialysis .</brief_summary>
	<brief_title>Safety , Tolerability , PK &amp; PD Study JTZ-951 Anemic Subjects With End-stage Renal Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Subjects ESRD receive maintenance hemodialysis least 12 week prior Screening Visit Body weight ( postdialysis weight ) great 45.0 kg body mass index 20.0 40.0 kg/m2 ( inclusive ) Screening Visit Hemoglobin value define protocol Meet erythropoiesisstimulating agent ( ESA ) therapy criterion Screening Visit define protocol Transferrin saturation ferritin level Screening Visit define protocol Anemia due know cause chronic kidney disease Known history hyporesponsiveness ESAs Acute coronary syndrome ( e.g. , myocardial infarction ) within 1 year prior Screening visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>hemodialysis</keyword>
</DOC>